Dasatinib for use in the treatment, regression or decelerating the progress of fibrotic lung diseases

Creative Commons License

ÖZTAY F., Yılmaz Ö.

Other, pp.1-6, 2016

  • Publication Type: Other Publication / Other
  • Publication Date: 2016
  • Page Numbers: pp.1-6
  • Istanbul University Affiliated: Yes

Abstract

The present invention relates to the use of dasatinib or its pharmaceutically acceptable salts thereof as a potential pharmaceutical agent, more preferably anti-proliferative or anti-fibrotic agent in fibrotic lung diseases, in particular idiopathic pulmoner fibrosis (IPF) disease.